![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » REPLIGEN Q4 NET LOSS WIDENS ON LOWER REVENUES, HIGHER OPERATING EXPENSES
REPLIGEN Q4 NET LOSS WIDENS ON LOWER REVENUES, HIGHER OPERATING EXPENSES
June 8, 2006
Thursday morning, Repligen Corp., a biopharmaceutical company, revealed fourth quarter results, reporting a net loss that widened on higher operating expenses and on a 4% decline in revenues.
Trading
Markets
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct